BioMarin To Present ROCTAVIAN Data From Longest And Largest Hemophilia Gene Therapy Clinical Trial Program At The International Society On Thrombosis And Haemostasis 2023 Congress
Portfolio Pulse from Benzinga Newsdesk
BioMarin Pharmaceutical (BMRN) will present data from the longest and largest hemophilia gene therapy clinical trial program, ROCTAVIAN, at the International Society on Thrombosis and Haemostasis 2023 Congress.
June 22, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin's presentation of ROCTAVIAN data at the International Society on Thrombosis and Haemostasis 2023 Congress may positively impact its stock price.
The presentation of ROCTAVIAN data from the longest and largest hemophilia gene therapy clinical trial program at a prestigious international congress may generate positive attention for BioMarin and its stock. This could lead to increased investor interest and a potential rise in BMRN's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100